Quest Diagnostics
DGX
#1023
Rank
$20.03 B
Marketcap
$179.43
Share price
-0.19%
Change (1 day)
29.12%
Change (1 year)
Quest Diagnostics is an American clinical laboratory company offering access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders and employment and court ordered drug testing.

P/E ratio for Quest Diagnostics (DGX)

P/E ratio as of June 2025 (TTM): 22.4

According to Quest Diagnostics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.422. At the end of 2024 the company had a P/E ratio of 19.4.

P/E ratio history for Quest Diagnostics from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202419.46.74%
202318.2-6.41%
202219.478.04%
202110.9-3.03%
202011.2-33.04%
201916.88.69%
201815.4-11.69%
201717.5-13.01%
201620.139.08%
201514.5-17.42%
201417.583.14%
20139.56-42.74%
201216.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
LabCorp
LH
30.0 33.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Psychemedics
PMD
-3.75-116.73%๐Ÿ‡บ๐Ÿ‡ธ USA
NeoGenomics
NEO
-11.5-151.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Enzo Biochem
ENZB
-2.32-110.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Translate Bio
TBIO.defunct
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Qiagen
QGEN
109 384.55%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.